Bempedoic acid helps lower cholesterol in Statin-intolerant patients
Cholesterol is a pale yellow steroid fat that is transported in the blood plasma and found in the cell membranes of body tissues. High cholesterol is a condition in which blood cholesterol levels are higher than normal. When cholesterol levels are higher than normal, LDL fat deposits in the blood vessels. These deposits can interfere with blood flow through the arteries. As a result, the heart does not receive enough oxygen-rich blood and can cause heart attacks. Reduced blood flow to the brain can also cause a stroke.
Bempedoic acid works by blocking a key enzyme, which is used by the body to make cholesterol, specifically it doesn’t accumulate in the muscles, reducing the likelihood of muscle pain. If approved by the FDA, Bempedoic acid could be a more effective and appropriate adjunct to cholesterol-lowering goals for patients.
Closed-cycle spinal cord stimulation in the treatment of chronic pain
Chronic pain is an exacerbation of recurrent pain that persists for more than 3 months. Patients with chronic pain lead to psychological disorders such as anxiety, depression, mood changes that affect daily social activities.
Closed-cycle spinal cord stimulation allows the implantable device to better interact with the spinal cord, being able to communicate in real time with spinal nerve cells. This is the first time there is a system that can measure the nerve’s response to stimulation and adjust every electrical impulse to real activity. Closed cycle spinal cord stimulation is now indicated in European countries and offers relief to chronic pain patients everywhere.
Biotechnology in orthopedic surgery
Biotechnology – consisting of cellular components, blood components, growth factors and other natural substances – has the power to replace or harness the body’s own power and promote healing and reduce inflammation in treatment. These factors are changing orthopedic surgery technology, allowing rapid improvement in treatment outcomes.
This new biotechnological technique uses a sponge injected with autologous biological factors combined with the patient’s own blood to stimulate healing of the anterior cruciate ligament, i.e., preserving tissue, not excision. it. Biotechnology holds great potential in providing every orthopedic surgery patient a faster, more natural, more effective recovery.
Topical coating antibiotics prevent infection of implanted heart-support devices
Worldwide, approximately 1,5 million patients undergo these heart-supporting electronic device surgeries each year. Infection is a dangerous complication during implantation of these devices. cough is by far the best and only proven way to prevent infection. Even so, infections continue to occur.
The recent development of a topical antibiotic product that helps ensure delayed release of two anti-infective drugs at the implant site for seven days after surgery. A delayed release over the course of a week will reduce the risk of infection. This trial’s initial record, published in March 3, showed a 2019% reduction in major infections, providing greater safety for cardiac implantation procedures for patients. .
Drugs for the treatment of myocardial Transthyretin Amyloid deposition disease
Myocardial Transthyretin amyloid deposition disease (ATTR-CM) is a rare, progressive, difficult to diagnose, potentially fatal, and previously untreated condition. Transthyretin amyloid deposition is usually diagnosed only after symptoms become severe and the average life expectancy in patients is about 2 to 3,5 years because treatment has previously been limited to heart transplants. a new drug – tafamidis (Vyndaquel developed by Pfizer) – stabilizes Transthyretin, slows amyloid formation, contributes to amyloid deposition in the myocardium, shows a significant reduction in the risk of death
May 5 marked the FDA’s approval of tafamidis, the first drug used to treat this increasingly concerning condition. Phase 2019 clinical trial results showed that tafamidis reduced the risk of death by 3% in patients receiving this breakthrough therapy.
PARP inhibitors – maintenance therapy in ovarian cancer
Ovarian cancer is a malignant tumor that originates in one or both ovaries. Cancer cells are abnormal cells that grow out of control and do not follow the body’s needs. And these cancer cells can invade and destroy surrounding tissues and organs. Not only that, they can metastasize to distant organs in the body and cause secondary cancer in that organ.
PARP (Poly ADP ribose polymerase) is an enzyme that repairs DNA damage and prevents cell suicide in the body, in other words PARP is a protein that tumors depend on to repair themselves. disability treatment. When the body has cancer, the cells take over this function of PARP and use it to help the tumor grow. Inhibiting the action of PARP to prevent repair of DNA damage and enhance cell death has soon become a promising therapy in cancer treatment and has entered clinical trials.
Dual-acting osteoporosis drug
Osteoporosis is a condition in which the bones become weak and fragile, the bones become thinner and the density in the bones becomes less and less, this makes the bones more brittle, vulnerable and increases the risk of fractures. Since 1995, the first drugs used to treat this condition have been limited to anti-wear effects, slowing bone loss. In 2002, anabolic drugs became popular with the main effect of increasing bone formation by stimulating osteoblasts. However, the stimulation found in these anabolic drugs also increases bone resorption, reducing some of their reinforcing effects.
Approved by the FDA in April 4, a new drug is overcoming this shortcoming. It is romosozumab (brand name Evenity developed by AMGEN) that is given by injection to patients twice a month for a year. New advances in the treatment of osteoporosis are providing benefits not only to the bones, but also to the mental well-being of patients and healthcare workers.
Enhancing the application of minimally invasive techniques in transcatheter mitral valve repair (Mitraclip)
Mitral regurgitation is relatively common, with an estimated 1 in 10 people over 75 years of age. Previously, to treat this disease, medicine could only use open-heart surgery with higher risks, and recovery time lasting many months.
In March 3, the FDA extended the approval of this minimally invasive technique to patients with secondary mitral regurgitation or mitral regurgitation due to left ventricular hypertrophy. The expansion of indications to patients with mitral regurgitation who have shown no signs of symptom deterioration after undergoing other treatments provides an important new treatment option for physicians and patients by Removes the fear and barrier associated with heart surgery, reducing the risk of treatment.
Treatment for peanut allergy
Peanuts are a common trigger for severe allergies with potentially life-threatening symptoms such as anaphylaxis. Currently, peanut allergies are on the rise in children. Recently, the development of a new oral immunotherapy product to gradually build up exposure to peanuts offers an opportunity for patients to fend off the onslaught of peanut allergy.
In September 9, an FDA panel of experts recommended the approval of a first-line therapy for peanut allergy. It is a capsule dosage form with very small amounts of peanut protein. Over time, the dose is increased and the child builds up an exposure to peanuts.